Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Shareholder Meeting (November 2018)
19 slides from Anatara Lifesciences's shareholder meeting presentation, Nov 12, 2018
Slide 1: Annual General Meeting
For personal use only Annual General Meeting 12 November 2018
Slide 2: Disclaimer
Disclaimer For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN
Slide 3: Key Investor Message
Key Investor Message For personal use only Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. 3
Slide 4: Company Highlights
Company Highlights For personal use only • Negotiated an exclusive global licensing agreement for the worldwide development, distribution and marketing of Detach with Zoetis Inc - #1 global animal health company • USD500K remainder of upfront payment received • Technical transfer complete • Detach r
Slide 5: Company Highlights Cont.
Company Highlights Cont. For personal use only • Human development program well underway - developing scientifically innovative and commercially attractive products for gastrointestinal health in areas of critical need • First product candidate - Gastrointestinal ReProgramming (GaRP) dietary supplem
Slide 6: Patient Stories
Patient Stories For personal use only You will now hear from three patients who are living with IBS or IBD and the impact it has on their lives. They will highlight their most difficult symptoms to manage and their own experiences with the effectiveness of current therapies and management practices.
Slide 7: Gastrointestinal ReProgramming (GaRP) Dietary Supplement
Anatara has designed a For personal use only novel product aimed at restoring and maintaining gut health: Gastrointestinal ReProgramming (GaRP) Dietary Supplement For the Management of Gastrointestinal Disorders 7
Slide 8: Target Gastrointestinal Disorders
Target Gastrointestinal Disorders For personal use only Irritable Bowel Syndrome (IBS) Inflammatory Bowel Disease (IBD) Affects around 11% of the global population1 >5 million sufferers globally2 Low grade inflammation Chronic inflammation Shared disease characteristics: Altered microbiome Impaired
Slide 9: The Microbiome and IBS/IBD
The Microbiome and IBS/IBD For personal use only Healthy gut microbiome • Supplies energy and nutrients • Immune system development • Defence against pathogens Healthy gut – increased diversity IBD/IBS gut microbiome • Less bacteria with anti-inflammatory properties • More bacteria with pro-inflamma
Slide 10: How GaRP works?
How GaRP works? For personal use only GaRP GaRPwill is abemicrobiome-targeted a microbiome-centric complementary medicine*aimed dietary supplement aimed at: at: Correcting gut Alleviation of Repair of gut microbiota the Reduction of lining and to restore symptomatic inflammation, barrier normal diar
Slide 11: Dietary Supplements as an adjunct to prescription drugs for the treatment of GI disorders
Dietary Supplements as an For personal use only adjunct to prescription drugs for the treatment of GI disorders • ~50% of patients seek additional relief of their symptoms through adjunct therapies • Increased education and more detailed evaluation of dietary supplements has led to health-care provi
Slide 12: GaRP – built on strong scientific foundations
For personal use only GaRP – built on strong scientific foundations 12
Slide 13: About bromelain
About bromelain For personal use only Generally Recognised Unlimited Acceptable But formal clinical as Safe (GRAS) Daily Intake (ADI) data has been lacking Bromelain is allowed in food as a Bromelain has been used for A lot of anecdotal evidence food additive and it has been decades in as an anti-in
Slide 14: Dual targeted product combining bromelain and other GRAS components
Dual targeted product combining bromelain and other GRAS components* For personal use only Ileum targeted components • prevent attachment of pro-inflammatory bacteria • restore gut microbiota • reduce inflammation Ileum Colon targeted components • restore gut microbiota • reduce inflammation • mucos
Slide 15: GaRP Development Plan
GaRP Development Plan • Commercial Feasibility- confirming the clinical and market need for a For personal use only multi-functional dietary supplement that could act as an adjunct to current IBD and IBS medications. • Proof of concept studies are well advanced to demonstrate that GaRP can: • Remove
Slide 16: Regulatory advantages of dietary supplements
Regulatory advantages of dietary supplements* For personal use only The advantages of a dietary supplement regulatory strategy are: 1. Less expensive and less risky pathway to market 2. Rapid market entry 3. Public and health care professionals understand the term ‘dietary supplement’ 4. Marketing c
Slide 17: A clear path to commercialisation
A clear path to commercialisation For personal use only 2017 2017 2018 2018 2019 2019 2020 2020 H1 H2 H1 H2 H1 H2 H1 H2 Confirmed GRAS status for ✓ components with FDA Established collaboration with ✓ University of Liverpool (UK) Completed product development ✓ plan Patent Application filed ✓ Commer
Slide 18: Product Development Advisory Board
Product Development Advisory Board For personal use only Professor Peter Gibson Dr Rebecca Burgell Dr Jakob Begun Professor Barry Campbell Professor Simon Keely • Advisory Board members are internationally recognised for their expertise in IBS and IBD with experience ranging from preclinical drug de
Slide 19: Thank you
For personal use only Thank you
Anatara Lifesciences — Shareholder Meeting (November 2018) on 6ix